Table 1.

Demographics and treatment characteristics of study cohorts: Neoadjuvant chemotherapy with SBRT versus chemotherapy with CRT.

	Total N = 168	SBRT N = 61	CRT N = 107	P
Male, %	96 (57%)	35 (57%)	61 (57%)	.963
Age, median (IQR)	64 (57–69)	61 (57–67)	65 (57–69)	.103
Preoperative staging
LAPC	84 (50%)	38 (62%)	46 (43%)	.017
BRPC	84 (50%)	23 (38%)	61 (57%)
Chemotherapy regimen
Capecitabine alone	18 (10.7%)	0	18 (16.8%)	< .001
5-fluorouracil alone	2	0	2
Gemcitabine alone	9 (5.3%)	2	7 (6.5%)
FOLFIRINOX *	70 (41.7%)	44 (72%)	26 (24.3%)
Other multiagent	69 (41.1%)	15 (25%)	54 (50.5%)
Total multiagent	139 (82.7%)	59 (97%)	80 (74.8%)	< .001

BRPC, borderline resectable pancreatic cancer; LAPC, locally advanced pancreatic cancer.

^*FOLFIRINOX: 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan.